期刊
PEDIATRICS
卷 119, 期 -, 页码 S166-S174出版社
AMER ACAD PEDIATRICS
DOI: 10.1542/peds.2006-2023J
关键词
glucocorticoids; bone mineral density; bone mineral content; glucocorticoid-induced osteoporosis; growth
类别
资金
- NCRR NIH HHS [M01RR00240] Funding Source: Medline
- NIDDK NIH HHS [R03-DK058200, R01-DK060030, K08-DK02523] Funding Source: Medline
Glucocorticoids inhibit osteoblasts through multiple mechanisms, which results in significant reductions in bone formation. The growing skeleton may be especially vulnerable to adverse glucocorticoid effects on bone formation, which could possibly compromise trabecular and cortical bone accretion. Although decreased bone mineral density has been described in various pediatric disorders that require glucocorticoids, and a population- based study reported increased fracture risk in children who require > 4 courses of glucocorticoids, some of the detrimental bone effects attributed to glucocorticoids may be caused by the underlying inflammatory disease. For example, inflammatory cytokines that are elevated in chronic disease, such as tumor necrosis factor alpha, suppress bone formation and promote bone resorption through mechanisms similar to glucocorticoid- induced osteoporosis. Summarized in this review are changes in bone density and dimensions during growth, the effects of glucocorticoids and cytokines on bone cells, the potential confounding effects of the underlying inflammatory- disease process, and the challenges in interpreting dual- energy x- ray absorptiometry results in children with altered growth and development in the setting of glucocorticoid therapy. Two recent studies of children treated with chronic glucocorticoids highlight the differences in the effect of underlying disease, as well as the importance of associated alterations in growth and development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据